May 10, 2018 / 11:15 AM / 18 days ago

BRIEF-Matinas Biopharma Holdings Reports Q1 Loss Per Share Of $0.05

May 10 (Reuters) - Matinas BioPharma Holdings Inc:

* MATINAS BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

* Q1 LOSS PER SHARE $0.05

* MATINAS - EXPECTS TO COMMENCE PIVOTAL PHASE 2 ADAPTIVE-DESIGNED STUDY FOR MAT2203 FOLLOWING ITS NEXT INTERACTION WITH FDA IN FIRST HALF OF 2019

* ENDED QUARTER WITH CASH AND CASH EQUIVALENTS OF APPROXIMATELY $4.3 MILLION

* COMPANY BELIEVES THAT CASH ON HAND IS SUFFICIENT TO FUND OPERATIONS INTO SEPTEMBER 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below